CoronaVac, a vaccine from Butantan and Chinese pharmaceutical company Sinovac, is proven to be safe and effective for individuals over 60 years of age. This is reinforced by Ana Marisa Chudzinski-Tavassi, director of innovation at Instituto Butantan and at the Center of Excellence in New Target Discovery (CENTD). Since the elderly are more susceptible to the serious effects of the disease, they were the first to receive the vaccine in Brazil and in several other countries.
This is one of the topics to be discussed during the CoronaVac Symposium, an international event to be held on the 7th, 8th and 9th of December by Instituto Butantan and Sinovac. The meeting will bring together Brazilian researchers from different areas and specialists from the United States, Turkey, Chile, China and Spain.
The scientist points out that all countries that administered the immunizing agent to the elderly observed a reduction in the number of deaths in this population. “So, obviously, CoronaVac is effective and safe for the adult and elderly population”, says Ana Marisa.